{"name":"TerSera Therapeutics LLC","slug":"tersera-therapeutics-llc","ticker":"","exchange":"","domain":"terserallc.com","description":"TerSera Therapeutics LLC is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for various medical conditions. The company has a pipeline of four drugs, including Xermelo, which is already marketed, and several others in Phase 2 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Xermelo","genericName":"Xermelo","slug":"xermelo","indication":"Diarrhea","status":"marketed"}]}],"pipeline":[{"name":"Xermelo","genericName":"Xermelo","slug":"xermelo","phase":"marketed","mechanism":"Tryptophan 5-hydroxylase 1","indications":["Diarrhea"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNNzNlU2Z4bHVNVV9uZ1RLczFuWGVadUE3MHk0Q09ydjJWbkRpUW5UWHJFN2V2cGY2NFJ0MndiWllIa1Y1ZEtpRS1tY1VpSWN0Rm5VOXRON3RQOHlqeVc4V01yME4wNzhWOE5pTG1PSGVVV1p6elhvSWFPRE16UVlNX2NnMjhtVHVmTzRlTHk0bHFvNmVBZDNXTHcxVXdKb0tlR3BJUE1JRVNsTm42MEU0ZVRQY2NmN1ZwLTVqbFBOSkMxU1I1TnlpOERWYUk4SzBaM24zcEFzSjN4WGtwWkhVLUN1MWYxY2JPb292cVFmRkMtNUlwUzBEdVZn?oc=5","date":"2026-03-10","type":"pipeline","source":"Business Wire","summary":"TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE - Business Wire","headline":"TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOb3NIWlpzdUZjUWQxaHpEeUt2czBjVHRpbW56ZkNLWENSV0VfdTB4UXVRR1ZrRFlYNndFM1ZvcjJua3ZTSTJKTzVrcy1IQjNOSzl1X1NuMmlWR3UtRWJKX2hLeGhoWGFqejJkNWg1M05jYl9EZzR1UzcwNVUyZnF6MXhyeUdVdy16MDZuWHdBdEhIN0oyQkd2U1JtanBlMUFmeHBaVzhmZktmcXpnR0k4TUx0RWRCb3JPS3pqdXRLaXJRZVpxeEhXNlNrb1M3WjFkdkVHZjZIMGVuR0tWd3h2bXNsNUhGaTZqbTFvQmFHTzM?oc=5","date":"2026-01-13","type":"deal","source":"PR Newswire","summary":"ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence - PR Newswire","headline":"ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5ZS3lWQ2ItRWRVcU1pampvSFZ6QWlvS3FCZ1FydU92VUpxVzg4aGhhOEo2eG5oWVJwaGlNUHVVcUVQakdEaVVwejloSkZLMHJLMmhGdFVJY1pnV1FCT2RVSER3Q0NDUm9FOVlETzd3?oc=5","date":"2022-08-11","type":"deal","source":"Anton Health","summary":"Limited Distribution Deals Announced - Anton Health","headline":"Limited Distribution Deals Announced","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQMnk5QjUzdEFUVTZIckZ6UUEwRUF2TldRM203YXk0TTdEQzdTQjRiTnlvbVIwUnpDUHhZSUZkY1RKV3Fwak1yQVVBNzN4WXZhaGtJWG5IS1NKUXhTUEkxcDM1YkxjbGU1MTQtTTZ6X3QzcHBuSk8wOW1tQmFld2FJTTVRZFhpTXJaUjlDVF8xcnRpWHl6UFJENC0xcVVhVUdpQXpLVEloQS1OcWd2X2U3S3I3ZWRDQVlP?oc=5","date":"2020-08-03","type":"pipeline","source":"PR Newswire","summary":"GTCR and TerSera Therapeutics Announce Acquisition of Xermelo - PR Newswire","headline":"GTCR and TerSera Therapeutics Announce Acquisition of Xermelo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQSlhDS1dnYWVjMWJKZENQcmJKSzZlYUItWUpfazkxSTBEeHE3SFlvQmJZSV9QUGF0Z3h4SUROV2F2VnIxaGloMWwzc1p4WmpzaGgwMWNrRldQcnpvMDlqQjZXZENmSmpTQkRtMi1yeGJ2M0s3anlLMEx4SE9Ed2JDSlZJWllianlRUGhITHlMYVZFdHV1ZE5Sb0ZHN01PN1U0MFlr?oc=5","date":"2018-07-03","type":"pipeline","source":"Contract Pharma","summary":"Jazz Pharma Sells Prialt Rights to TerSera Therapeutics - Contract Pharma","headline":"Jazz Pharma Sells Prialt Rights to TerSera Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQbzktOXRhUW1ZbEFxOENWYWptMGl1QUFucjVYM1NwcnNNRnRlR1FyNzVRVTJqaUVTZmZGR1NxMi03TWZtbmJRanpNRm11c1JPVFhFRUhWOW9IdTR1NUdOZEViWkNmQkY1UVZvQ2JWVHBJbnJaRF81bEs3d1Fldm1vLV9kTE5TM0M0bVN3MXY2XzRqNzJ6TF8yamNUa3VPVVVFdmhTR25EZUQ1ckZRZlJzTGEyM1JBeTRHaG9hZ0tkS1FRQ2hGRm5CcUFIMWFRb0VBWkFKUG9n?oc=5","date":"2018-06-29","type":"pipeline","source":"PR Newswire","summary":"Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt - PR Newswire","headline":"Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNdjlMcUw1cld2Z3FoTTBJRE5aaTNDaWMzMk83dWlkUUE3NFdwT01mYkJ5UFJuOWRLWHN6bmdOekRWUUF3YXhOTjJLQzdsck9vZG84cDFrUFNubklOWjdBbkNhNzBRQzllamt4NWJ0WVBWcVRQdDI4dmpPcG5ZanU3cnJYbWcwM3FhZ0J1TnExMHhrVFhNbldIdnU5cFRjdV9MQ1hUUXhRNzVKUXV4a2ZjX0lMeUg5MExQYkdpbllKWWotMHQ0WG1MSnJkb2tTaHJWX0J0LUdOMjVfaGdTOERmTDdpbnlwV3B5Mjg2SUxnN0NDdElL?oc=5","date":"2017-02-20","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada - AstraZeneca","headline":"AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQQWtfNlBvWHVSSUFLcFNoelhYVGx6MnphSGkwYlNiX0NMeF9XVTk4UW03SkNaUzg2WFpCaFF3RFM0VHNBSVlPRnBwQVZQLWhMM3JQSlpaSnBaZFNBdFJiclQzbHAxTVNVajEtYjExVDN5SkJ5NExoMjhTazBvdUxkWUp3?oc=5","date":"2016-02-05","type":"pipeline","source":"BioSpace","summary":"GTCR, Ed Fiorentino Form New Company TerSera - BioSpace","headline":"GTCR, Ed Fiorentino Form New Company TerSera","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":9,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}